Guest
🎯 Загружено автоматически через бота: 🚫 Оригинал видео: 📺 Данное видео принадлежит каналу «Inside China Business» (@Inside_China_Business). Оно представлено в нашем сообществе исключительно в информационных, научных, образовательных или культурных целях. Наше сообщество не утверждает никаких прав на данное видео. Пожалуйста, поддержите автора, посетив его оригинальный канал. ✉️ Если у вас есть претензии к авторским правам на данное видео, пожалуйста, свяжитесь с нами по почте support@, и мы немедленно удалим его. 📃 Оригинальное описание: American officials are passing new regulations intended to drive Chinese companies out of our pharmaceutical supply chains. And drug companies seem to concur, as they say publicly that they, too, need to diversify away from China. The reality is the opposite. US and European drugmakers make enormous profits from the drugs that are manufactured in China, then licensed for sale in the American market. Their motivation is the enormous price difference, between what patients pay in the United States, compared to the rest of the world. Resources and links: Substack, for video transcript and direct links Novo’s Wegovy Launched in China at a Fraction of US Price Bloomberg, Novo Nordisk Launches Wegovy in China With Prices Below US Fortune, Novo Nordisk launches Wegovy in China with prices well below U.S. China’s Rising Role On The Global Stage In The Oncology Market Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer The US is relying more on China for pharmaceuticals — and vice versa Major Life Sciences Licensing Deal Trends in China in 2023 Wall Street Journal, U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners Reuters, Merck signs up to $3.3 billion cancer drug deal with China-based LaNova Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster PBS, How Russian oil is reaching the U.S. market through a loophole in the embargo CBS News/60 Minutes, Russia works around international sanctions designed to cripple the economy amid war with Ukraine Politico, Grappling with supply chain crunch A Bilateral Approach to Address Vulnerability in the Pharmaceutical Supply Chain Closing scene, Blue Moon Valley, Lijiang, Yunnan
